Global trends and collaboration in ovarian tissue transplantation: a 20-year bibliometric analysis
Wu T., Zhao Y., Chen Y., Nie K., Yan J., Zhang J.
Prospective Study, published in Reprod Fertil (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Reprod Fertil (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41026645
- PMCID
- PMC12579510
- DOI
- 10.1530/raf-25-0022
Abstract (original English)
Abstract Ovarian tissue transplantation is vital for preserving fertility in female cancer survivors. Since the first human ovarian tissue transplantation in 2000 and the first live birth in 2004, it has received much more attention. However, the research scale, core research teams, and publication quality have not been systematically documented. This lack of foundational data hinders researchers' ability to assess the maturity and prevailing trends within the domain, potentially leading to duplicated efforts and suboptimal resource allocation. Our study addresses this gap by analyzing ovarian tissue transplantation research from 2000 to 2023 to map academic performance and collaboration networks. Key findings reveal Belgium and the USA as leading contributors, with robust international collaboration driving progress. The Université Catholique Louvain emerged as the most productive institution, while Dolmans M.M. stood out as a pivotal researcher. Human Reproduction ranked as the top journal for disseminating OTT advancements. Research trends highlight sustained focus on 'tissue cryopreservation', 'activation', and 'live-birth' through 2023, with disease indications shifting from 'breast cancer' and 'chemotherapy' toward 'infertility', 'leukemia', and 'premature ovarian failure'. This study offers crucial insights and understanding for collaborative work among researchers in th
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.